COMPANY BACKGROUND

Ajax Therapeutics is pursuing uniquely selective approaches to develop novel small molecules targeting key cytokine signaling pathways that drive hematologic malignancies. By combining the deep cancer and structural biology insights of our founding scientists with the industry's most advanced computational drug discovery platform from our founding partner, Schrodinger, Inc, we aim to discover and develop more precisely designed therapies to address significant unmet needs for patients with hematologic malignancies.

ROLE: HEAD (VP) OF PRECLINICAL DEVELOPMENT

Responsible for all aspects of preclinical development to advance Company's drug programs from discovery to the clinic. Represent the Company in a wide range of interactions, both internally and externally, for all nonclinical bioanalysis, drug metabolism and pharmacokinetics, and nonclinical toxicology activities. Manage and lead all aspects of clinical and nonclinical Drug Metabolism and Pharmacokinetics and nonclinical toxicology, incorporating emerging technologies and relevant applications. Significantly contribute to and lead the selection of compounds in Drug Discovery process. Use creative and proactive problem solving to design IND enabling toxicology studies, development and reproductive toxicology studies, chronic toxicology studies, carcinogenicity, and genotoxicity testing of drugs to aggressive timelines. Prepare related DMPK and toxicology studies for regulatory filings (e.g., IND and NDA). Propose activities for cross-functional technology relevant to project objectives. Build strong working relationships with drug substance and drug product partners.

PROFESSIONAL EXPERIENCE/QUALIFICATIONS

- Minimum of 15 years of relevant industry experience.
- Expertise in technical, scientific, and regulatory aspects of non-clinical safety evaluation.
- Proven ability to design, manage and interpret outsourced non-clinical safety studies in rodent and non-rodent (NHP) species.

- Demonstrated ability to tackle complex scientific problems to enable first in man dosing or progression of programs into late-stage development.
- Previous experience having progressed small molecules or biologics through clinical development or registration is a plus.
- Comprehensive understanding of the interplay between non-clinical safety, pharmacology, biomarkers, DMPK and formulations.
- Experience with investigative toxicology including proven ability to research and develop strategy around novel findings.
- Extensive experience interfacing with, and providing scientific guidance to, CRO partners and proven ability to work efficiently in a hybrid model.
- Experience interacting with worldwide regulatory agencies and authoring regulatory filings.
- Proven success in supporting cross-functional project teams and ability to collaborate in a cross-functional matrixed organization.
- Strong oral communication skills and demonstrated proficiency at technical writing are essential.
- Ability to integrate data across disciplines and communicate salient data to executive leadership and/or a broad audience.
- Strong preference for experience in small molecule oncology discovery.
- DABT and/or DACVP is preferred.

EDUCATION

PhD in toxicology or related field or DVM.

COMPENSATION

An attractive compensation package commensurate with this senior leadership role will be provided.